Nevertheless, despite the incomplete comprehension of the nature and distribution of CD32 putative ligand(s), CD32-CR T cell–based immunotherapy, alone or in association with anti-EGFR therapeutic mAbs (Caratelli et al, 2020), might be used for designing rational immunotherapies for targeting BC as suggested by in vivo results. The gene discussed is FCGR2A; the disease is breast cancer.